The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Quality of life analysis from a multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 versus radium-223 in metastatic castration-resistant prostate cancer with bone metastases (COMRADE).
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Precede Bio; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Wanling Xie
Consulting or Advisory Role - Prostate Cancer Clinical Trial Consortium
 
Archana Ajmera
Honoraria - NCCN
Consulting or Advisory Role - Janssen Biotech
 
Arlene Araneta
No Relationships to Disclose
 
Edmund Folefac
No Relationships to Disclose
 
Arif Hussain
No Relationships to Disclose
 
Christos Kyriakopoulos
Employment - Epic Systems (I)
Stock and Other Ownership Interests - Biogen; Epic Systems (I)
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Janssen Oncology; Pfizer; Sanofi
Research Funding - AstraZeneca; Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); ESSA; Gilead Sciences; Madison Vaccines, Inc. (Inst); Pionyr; Sanofi
 
Adam Olson
Consulting or Advisory Role - RenovoRx
Travel, Accommodations, Expenses - Bioprotect
 
Rahul Parikh
Stock and Other Ownership Interests - IBRX (I); PSTV (I); Rocket Pharma (I)
Patents, Royalties, Other Intellectual Property - Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.
 
Salma Jabbour
Consulting or Advisory Role - Advarra; AstraZeneca; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Radialogica
Research Funding - Beigene (Inst); Guardant Health (Inst); Haystack Oncology (Inst); Merck Sharp & Dohme (Inst); NCI (Inst)
Expert Testimony - deichert
Travel, Accommodations, Expenses - AstraZeneca; Merck
 
Geoffrey Shapiro
Consulting or Advisory Role - Circle Pharmaceuticals; Concarlo Therapeutics; FoRx Therapeutics; Merck Serono; MycRx; Schrodinger
Research Funding - Artios (Inst); Bristol-Myers Squibb/Medarex (Inst); Lilly (Inst); Merck Serono (Inst); Pfizer (Inst); Sumitomo Pharma Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patent # 10,934,593 B2 Compositions and methods for predicting response and resistance to CDK4/6 inhibition; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018